TY - JOUR
T1 - Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update
T2 - what's changed and why it matters
AU - Ketteler, Markus
AU - Block, Geoffrey A.
AU - Evenepoel, Pieter
AU - Fukagawa, Masafumi
AU - Herzog, Charles A.
AU - McCann, Linda
AU - Moe, Sharon M.
AU - Shroff, Rukshana
AU - Tonelli, Marcello A.
AU - Toussaint, Nigel D.
AU - Vervloet, Marc G.
AU - Leonard, Mary B.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD Guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with chronic kidney disease (CKD), those on chronic dialysis therapy, or individuals with a kidney transplant. This review highlights key aspects of the 2017 CKD-MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document. Topic areas encompassing updated recommendations include diagnosis of bone abnormalities in CKD–mineral and bone disorder (MBD), treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD-MBD, treatment of bone abnormalities by antiresorptives and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease.
AB - The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD Guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with chronic kidney disease (CKD), those on chronic dialysis therapy, or individuals with a kidney transplant. This review highlights key aspects of the 2017 CKD-MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document. Topic areas encompassing updated recommendations include diagnosis of bone abnormalities in CKD–mineral and bone disorder (MBD), treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD-MBD, treatment of bone abnormalities by antiresorptives and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease.
KW - KDIGO CKD-MBD Guideline
KW - bone mineral density
KW - calcium
KW - dialysis
KW - hyperparathyroidism
KW - hyperphosphatemia
KW - kidney transplantation
UR - http://www.scopus.com/inward/record.url?scp=85021339948&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.kint.2017.04.006
DO - https://doi.org/10.1016/j.kint.2017.04.006
M3 - Review article
C2 - 28646995
SN - 0085-2538
VL - 92
SP - 26
EP - 36
JO - Kidney International
JF - Kidney International
IS - 1
ER -